NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTION
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
AUVI-Q (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. First approved in 2012.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AUVI-Q is a pre-filled, auto-injectable epinephrine solution approved for emergency treatment of anaphylaxis across multiple allergen triggers. It works as an alpha-adrenergic agonist, rapidly reversing life-threatening allergic reactions by restoring airway patency and cardiovascular stability. The product represents a convenience-focused reformulation of a legacy injectable, enabling rapid self-administration in acute settings.
$0.719MPart D
Peak11.5 years to LOEProduct is in peak lifecycle with stable but modest Medicare Part D penetration; brand team size likely lean with focus on market access and patient education rather than growth expansion.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started May 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Started Sep 2025
30 enrolled
Distributive ShockHemodynamic AssessmentCritical Illness
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Started Apr 2025
186 enrolled
Intraoperative Bradycardia
Worked on AUVI-Q at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.